ImmuSmol is specialized in developing antibodies directed against small molecules. Supported by public institutions including BPI, Conseil Régional Nouvelle Aquitaine, as well as by its Co-founder Associate – SCHIEVER, Immusmol is established in Bordeaux, France.
The ImmuSmol team is made up of around twenty talents with different backgrounds and application fields, bringing their expertise and experience to the company. ImmuSmol aims to become a natural choice for small molecule antibodies development, collaborating with a worldwide network of scientists.
ImmuSmol’s focus: validated tools for detecting small molecules
ImmuSmol stands for antibodies against small molecules. While traditional antibodies only recognize large molecules such as proteins, ImmuSmol designs and develops antibodies capable of targeting low molecular weight entities, below 900 Daltons, that can be used for conventional staining applications as well as in the scope of novel immunoassays development
Their products are fully compatible with existing antibody-based technologies, small molecule antibodies are opening a whole new set of possibilities in research diagnostic and therapeutic applications.
The prices are on request! Contact Us by e-mail info@sobekbio.com
Molnova is a global bio-tech enterprise, specializing in chemical and biological research products with service to meet the research needs of their global customers. Molnova has evolved into one of the biggest global compounds and peptides supplier with over 9000 products from over 20 singnaling pathways and 400 targets. They carry a broad product line over different research areas such as cancer, infection, immunology, neurosciences, apoptosis and metabolic disorder, etc.
Molnova offers a wide range of high quality research chemicals including novel life-science reagents, inhibitors, peptides, activator, APIs and natural compounds for scientific use. Molnova also provides cutting edge custom services including chemical synthesis, peptide synthesis, drug screening and contract research services. Innovation plays a key role in their company's progress. Molnova focuses on novel target and novel candidate compounds for pre-clinical drug research. Besides, bring more than 1000 new products each year to help their customers achieve their project.
Molnova has a talented team of scientists and technical staff with experience in the biotech and pharma industry. Molnova’s mission is to provide top-notch life sciences products, innovative solutions to scientists worldwide and hit your research to lead.
website: www.molnova.com
The prices are on request! Contact Us by e-mail info@sobekbio.com
DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore, companies can have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.
Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:
Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock.
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry.
The prices are on request! Contact Us by e-mail info@sobekbio.com
| 0.1 mg |
Clonality:
Polyclonal
Host:
Rabbit
Isotype:
IgG
Clone name:
Applications:
WB, IHC, E
Storage:
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com